AstraZeneca may have provided incomplete efficacy data from latest Covid-19 trial: NIAID | The Business Standard
Skip to main content
  • Latest
  • Epaper
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Monday
June 16, 2025

Sign In
Subscribe
  • Latest
  • Epaper
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
MONDAY, JUNE 16, 2025
AstraZeneca may have provided incomplete efficacy data from latest Covid-19 trial: NIAID

Coronavirus chronicle

Reuters
23 March, 2021, 11:00 am
Last modified: 23 March, 2021, 12:29 pm

Related News

  • US Health Secretary Kennedy guts vaccine advisory committee
  • Govt plans to relocate country's first vaccine plant from Gopalganj to Munshiganj
  • Umrah pilgrims struggle with abrupt meningitis vaccination requirement amid shortage
  • Vaccination, early screening can prevent cervical cancer death for women
  • Study on Bangladeshi children confirms lasting impact of typhoid vaccine

AstraZeneca may have provided incomplete efficacy data from latest Covid-19 trial: NIAID

AstraZeneca said a day earlier that its Covid-19 vaccine developed with Oxford University was 79% effective in preventing symptomatic illness in a large trial in Chile, Peru and the United States

Reuters
23 March, 2021, 11:00 am
Last modified: 23 March, 2021, 12:29 pm
Vials labelled "Astra Zeneca COVID-19 Coronavirus Vaccine" and a syringe are seen in front of a displayed AstraZeneca logo, in this illustration photo taken March 14, 2021. REUTERS/Dado Ruvic/Illustration/File Photo/File Photo
Vials labelled "Astra Zeneca COVID-19 Coronavirus Vaccine" and a syringe are seen in front of a displayed AstraZeneca logo, in this illustration photo taken March 14, 2021. REUTERS/Dado Ruvic/Illustration/File Photo/File Photo

AstraZeneca Plc may have provided an incomplete view of efficacy data on its Covid-19 vaccine from a large scale US trial, a US health agency said Tuesday in a fresh setback for the shot.

The news comes just one day after interim data from the drugmaker showed better-than-expected results from the trial and casts doubt on its plan to seek US emergency use authorization for the vaccine in the coming weeks.

The vaccine developed with Oxford University was 79% effective in preventing symptomatic illness in a large trial in the United States, Chile and Peru, and, crucially, posed no increased risk of blood clots, according to the data.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

The Data Safety Monitoring Board (DSMB) has "expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data," the US National Institute of Allergy and Infectious Diseases (NIAID) said in a statement.

NIAID is headed by US infectious diseases expert Anthony Fauci and is part of the National Institutes of Health.

"We urge the company to work with the DSMB to review the efficacy data and ensure the most accurate, up-to-date efficacy data be made public as quickly as possible," it said.

AstraZeneca did not immediately respond to a Reuters request for comment.

Authorization and guidelines for use of the vaccine in the United States will be determined after thorough review of the data by independent advisory committees, the statement added.

Hailed as a milestone in the fight against the Covid-19 pandemic when it emerged as a vaccine contender last year, the AstraZeneca shot has been dogged by doubts over its efficacy, dosing regimen and possible side effects.

More than a dozen European countries, including Germany and France, halted use of the vaccine earlier this month after reports linked it to a rare blood clotting disorder in a very small number of people.

The latest trial data, which have yet to be reviewed by independent researchers, was set to give credence to the British shot after results from earlier, separate late-stage studies raised questions about the robustness of the data.

Fauci, who also serves as chief medical advisor to US President Joe Biden, said on Monday the US trial found no indication at all of the rare blood clots.

The latest data was based on 141 infections among 32,449 participants.

The shot has also been at the centre of a growing conflict between Brussels and London over so-called vaccine nationalism after a string of supply setbacks in Europe.

Vaccine efficacy / vaccine data / Vaccine / Coronavirus Vaccine / covid-19 vaccine / AstraZeneca Covid-19 Vaccine / Oxford-AstraZeneca vaccine / AstraZeneca vaccine / AstraZeneca's vaccine / US National Institute of Allergy and Infectious Diseases (NIAID)

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Bangladesh High Commissioner to the United Kingdom Saida Muna Tasneem. Photo: Collected
    ACC launches inquiry against ex-UK envoy Saida Muna, husband over laundering Tk2,000cr
  • Photo collage of ousted former prime minister Sheikh Hasina, former home minister Asaduzzaman Khan Kamal and former inspector general of police Chowdhury Abdullah Al Mamun, all of them are accused in the case. Collage: TBS
    ICT orders newspaper ads summoning Hasina to appear before tribunal on 24 June
  • ACC Chairman Mohammad Abdul Momen at a press briefing on 16 June 2025. Photo: TBS
    UK crime agency to train ACC on bringing back laundered money

MOST VIEWED

  • Bangladesh Bank Governor Ahsan H Mansur. TBS Sketch
    Merger of 5 Islamic banks at final stage: BB governor
  • UCB launches Bangladesh's first microservices-based open API banking platform
    UCB launches Bangladesh's first microservices-based open API banking platform
  • Photo: Collected
    Pakistan rejects reports of missile supply to Iran
  • Non-performing loans surge by Tk74,570cr in Q1 as hidden rot exposed
    Non-performing loans surge by Tk74,570cr in Q1 as hidden rot exposed
  • Crore-taka bank accounts edge down by 719 in March quarter
    Crore-taka bank accounts edge down by 719 in March quarter
  • Nepal begins 38MW hydropower export to Bangladesh
    Nepal begins 38MW hydropower export to Bangladesh

Related News

  • US Health Secretary Kennedy guts vaccine advisory committee
  • Govt plans to relocate country's first vaccine plant from Gopalganj to Munshiganj
  • Umrah pilgrims struggle with abrupt meningitis vaccination requirement amid shortage
  • Vaccination, early screening can prevent cervical cancer death for women
  • Study on Bangladeshi children confirms lasting impact of typhoid vaccine

Features

The GLS600 overall has a curvaceous nature, with seamless blends across every panel. PHOTO: Arfin Kazi

Mercedes Maybach GLS600: Definitive Luxury

5h | Wheels
Renowned authors Imdadul Haque Milon, Mohit Kamal, and poet–children’s writer Rashed Rouf seen at Current Book Centre, alongside the store's proprietor, Shahin. Photo: Collected

From ‘Screen and Culture’ to ‘Current Book House’: Chattogram’s oldest surviving bookstore

21h | Panorama
Photos: Collected

Kurtis that make a great office wear

2d | Mode
Among pet birds in the country, lovebirds are the most common, and they are also the most numerous in the haat. Photo: Junayet Rashel

Where feathers meet fortune: How a small pigeon stall became Dhaka’s premiere bird market

4d | Panorama

More Videos from TBS

ICT orders newspapers ads summoning Hasina to appear before tribunal on 24 June

ICT orders newspapers ads summoning Hasina to appear before tribunal on 24 June

1h | TBS Today
Who was IRGC intelligence chief Kazemi killed in Israeli strike?

Who was IRGC intelligence chief Kazemi killed in Israeli strike?

1h | TBS World
Yunus-Tareq meeting; What Amir Khusru said after returning home after participating

Yunus-Tareq meeting; What Amir Khusru said after returning home after participating

2h | TBS Today
Iran launches missile attack on Israel again

Iran launches missile attack on Israel again

3h | TBS World
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net